Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy

Bioanalysis

Volumn 5, Issue 9, 2013, Pages 1099-1114

  St Denis, Tyler G ^a,b   Hamblin, Michael R ^b,c,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 ISOTHIOCYANATOPHENYL) 10,15,20 TRI(3,5 DIHYDROXYPHENYL)PORPHYRIN MONOCLONAL ANTIBODY 35A7 CONJUGATE; 5 (4 ISOTHIOCYANATOPHENYL) 10,15,20 TRI(3,5 DIHYDROXYPHENYL)PORPHYRIN MONOCLONAL ANTIBODY FSP 77 CONJUGATE; 5 (4 ISOTHIOCYANATOPHENYL) 10,15,20 TRIS(4 N METHYLPYRIDINIUM)PORPHYRIN TRICHLORIDE MONOCLONAL ANTIBODY 35A7 CONJUGATE; 5 (4 ISOTHIOCYANATOPHENYL) 10,15,20 TRIS(4 N METHYLPYRIDINIUM)PORPHYRIN TRICHLORIDE MONOCLONAL ANTIBODY FSP 77 CONJUGATE; 700 DX PANITUMUMAB CONJUGATE; 700 DX TRASTUZUMAB CONJUGATE; ALUMINUM TETRASULFOPHTHALOCYANINE MONOCLONAL ANTIBODY 35A7 CONJUGATE; ANTIBODY CONJUGATE; BARNASE; BENZOPORPHYRIN DERIVATIVE; CARCINOEMBRYONIC ANTIGEN; CHLORIN E6; CHLORIN E6 CETUXIMAB CONJUGATE; CHLORIN MONOCLONAL ANTIBODY OC125 CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM PORPHYRIN CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY CONJUGATE; HEMATOPORPHYRIN ANTIBODY CONJUGATE; HEMATOPORPHYRIN VASCULOTROPIN ANTIBODY CONJUGATE; HYDROGEN PEROXIDE; MACROGOL; PHENOTHIAZINE; PHOTOSENSITIZING AGENT; PORPHYRIN; PYROPHEOPHORBIDE A; QUANTUM DOT; REACTIVE OXYGEN METABOLITE; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN CETUXIMAB CONJUGATE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARCINOMA; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PURIFICATION; DRUG RETENTION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; HUMAN; LEWIS CARCINOMA; LYMPHOMA; MYOSARCOMA; NONHUMAN; OXIDATIVE STRESS; PHOTOCATALYSIS; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA;

ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; IMMUNOCONJUGATES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TISSUE DISTRIBUTION;

EID: 84877313102     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.37     Document Type: Review

References (69)

1. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one: photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn. Ther. 1(4), 279-293 (2004).
2. Raab O. Ueber diewirkung fluoreszierender stoffe auf infusori. Z. Biol. 39, 524-536 (1900).
3. Von Tappeiner H. Ueber die wirkung fluorescierenden stoffe auf infusiorien nach versuchen von O Raab. Munch. Med. Wochenschr. 47, 5 (1900).
4. Von Tappeiner H, Jesionek A. Therapeutische versuche mit fluorescierenden stoffen. Munch. Med. Wochenschr. 47, 2042-2044 (1903).
5. Von Tappeiner H, Joblauer A. Uber die wirkung der photodynamischen (fluorescierenden) staffe auf protozoan und enzyme. Dtsch Arch. Klin. Med. 80, 427-487 (1904).
6. Hamblin MR, Mróz P. Advances in Photodynamic Therapy: Basic, Translational, and Clinical. Artech House, MA, USA (2008).
7. Figge FH, Weiland GS, Manganiello LO. Studies on cancer detection and therapy; the affinity of neoplastic, embryonic, and traumatized tissue for porphyrins, metalloporphyrins, and radioactive zinc hematoporphyrin. Anat. Rec. 101(4), 657 (1948).
8. Hamblin MR, Newman EL. On the mechanism of the tumour-localising effect in photodynamic therapy. J. Photochem. Photobiol. B 23(1), 3-8 (1994).
9. Agostinis P, Berg K, Cengel KA et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61(4), 250-281 (2011).
10. Pervaiz S, Olivo M. Art and science of photodynamic therapy. Clin. Exp. Pharmacol. Physiol. 33(5-6), 551-556 (2006).
11. Van Dongen GA, Visser GW, Vrouenraets MB. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv. Drug Deliv. Rev. 56(1), 31-52 (2004).
12. Foote CS. Definition of type I and type II photosensitized oxidation. Photochem. Photobiol. 54(5), 659 (1991).
13. Nastri L, Donnarumma G, Porzio C et al. Effects of toluidine blue-mediated photodynamic therapy on periopathogens and periodontal biofilm: in vitro evaluation. Int. J. Immunopathol. Pharmacol. 23(4), 1125-1132 (2010).
14. Alonso CM, Palumbo A, Bullous AJ, Pretto F, Neri D, Boyle RW. Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies. Bioconjug. Chem. 21(2), 302-313 (2010).
15. Fabbrini M, Trachsel E, Soldani P et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int. J. Cancer 118(7), 1805-1813 (2006).
16. Hamblin MR, Miller JL, Hasan T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res. 56(22), 5205-5210 (1996).
17. An Z. Monoclonal antibodies-a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1(4), 319-330 (2010).
18. Mew D, Wat CK, Towers GH, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol. 130(3), 1473-1477 (1983).
19. Soukos NS, Hamblin MR, Keel S, Fabian RL, Deutsch TF, Hasan T. EGF receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res. 61(11), 4490-4496 (2001).
20. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 17(12), 1685-1691 (2011).
21. Oseroff AR, Ohuoha D, Hasan T, Bommer JC, Yarmush ML. Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc. Natl Acad. Sci. USA 83(22), 8744-8748 (1986).
22. Mayo GL, Melendez RF, Kumar N, Mckinnon SJ, Glickman RD. Antibody-targeted photodynamic therapy. Am. J. Ophthalmol. 136(6), 1151-1152 (2003).
23. Hongrapipat J, Kopeckova P, Liu J, Prakongpan S, Kopecek J. Combination chemotherapy and photodynamic therapy with fab́ fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol. Pharm. 5(5), 696-709 (2008).
24. Rancan F, Helmreich M, Molich A et al. Synthesis and in vitro testing of a pyropheophorbide-a-fullerene hexakis adduct immunoconjugate for photodynamic therapy. Bioconjug. Chem. 18(4), 1078-1086 (2007).
25. Hamblin MR, Bamberg MP, Miller JL, Hasan T. Cationic photoimmunoconjugates between monoclonal antibodies and hematoporphyrin: selective photodestruction of ovarian cancer cells. Appl. Opt. 37(31), 7184-7192 (1998).
26. Jiang FN, Jiang S, Liu D, Richter A, Levy JG. Development of technology for linking photosensitizers to a model monoclonal antibody. J. Immunol. Methods 134(1), 139-149 (1990).
27. Hemming AW, Davis NL, Dubois B, Quenville NF, Finley RJ. Photodynamic therapy of squamous cell carcinoma. An evaluation of a new photosensitizing agent, benzoporphyrin derivative and new photoimmunoconjugate. Surg. Oncol. 2(3), 187-196 (1993).
28. Savellano MD, Hasan T. Targeting cells that overexpress the EGF receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol. 77(4), 431-439 (2003).
29. Lindmo T, Bunn PA Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol. 121, 678-691 (1986).
30. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72(1), 77-89 (1984).
31. Konishi S, Hamacher K, Vallabhajosula S et al. Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? Cancer Biother. Radiopharm. 19(6), 706-715 (2004).
32. Stanley C, Lew AM, Steward MW. The measurement of antibody affinity: a comparison of five techniques utilizing a panel of monoclonal anti-DNP antibodies and the effect of high affinity antibody on the measurement of low affinity antibody. J. Immunol. Methods 64(1-2), 119-132 (1983).
33. Franceschi A, Dosio F, Anselmi C et al. Mechanisms involved in serum-dependent inactivation of the immunotoxin enhancers monensin and carrier-protein-monensin. Eur. J. Biochem. 219(1-2), 469-479 (1994).
34. Gottschalk U, Garnett MC, Ward RK, Maibucher A, Kohnlein W. Increased serum stability and prolonged biological half-life of neocarzinostatin covalently bound to monoclonal antibodies. J. Antibiot. (Tokyo) 44(10), 1148-1154 (1991).
35. Rihova B, Kopeckova P, Strohalm J, Rossmann P, Vetvicka V, Kopecek J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46(1), 100-114 (1988)
36. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54(4), 531-545 (2002).
37. Hudson R, Carcenac M, Smith K et al. The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy. Br. J. Cancer 92(8), 1442-1449 (2005).
38. Hamblin MR, Del Governatore M, Rizvi I, Hasan T. Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer. Br. J. Cancer 83(11), 1544-1551 (2000).
39. Duska LR, Hamblin MR, Bamberg MP, Hasan T. Biodistribution of charged F(ab́)2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer 75(6), 837-844 (1997).
40. Linares R, Pacheco JR, Good TA. Efficacy of different targeting agents in the photolysis of interleukin-2 receptor bearing cells. J. Photochem. Photobiol. B 77(1-3), 17-26 (2004).
41. Savellano MD, Hasan T. Photochemical targeting of EGF receptor: a mechanistic study. Clin. Cancer Res. 11(4), 1658-1668 (2005).
42. Zdobnova TA, Stremovskiy OA, Lebedenko EN, Deyev SM. Self-assembling complexes of quantum dots and scFv antibodies for cancer cell targeting and imaging. PLoS ONE 7(10), e48248 (2012).
43. Vrouenraets MB, Visser GW, Loup C et al. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: a new possibility for use in photodynamic therapy. Int. J. Cancer 88(1), 108-114 (2000).
44. Sibrian-Vazquez M, Jensen TJ, Vicente MG. Synthesis, characterization, and metabolic stability of porphyrin-peptide conjugates bearing bifunctional signaling sequences. J. Med. Chem 51(10), 2915-2923 (2008).
45. Lu ZR, Kopeckova P, Kopecek J. Polymerizable Fab́ antibody fragments for targeting of anticancer drugs. Nat. Biotechnol. 17(11), 1101-1104 (1999).
46. Mendelsohn J, Baselga J. EGF receptor targeting in cancer. Semin. Oncol. 33(4), 369-385 (2006).
47. Roby A, Erdogan S, Torchilin VP. Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biol. Ther. 6(7), 1136-1142 (2007).
48. Abu-Yousif AO, Moor AC, Zheng X et al. EGF receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett. 321(2), 120-127 (2012).
49. Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, Van Dongen GA. Comparison of aluminium (III) phthalocyanine tetrasulfonate-and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro. Int. J. Cancer 98(5), 793-798 (2002).
50. Kuimova MK, Bhatti M, Deonarain M et al. Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy. Photochem. Photobiol. Sci 6(9), 933-939 (2007).
51. Stuchinskaya T, Moreno M, Cook MJ, Edwards DR, Russell DA. Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyanine-gold nanoparticle conjugates. Photochem. Photobiol. Sci. 10(5), 822-831 (2011).
52. Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res. 65(14), 6371-6379 (2005).
53. Sarobe P, Huarte E, Lasarte JJ, Borras-Cuesta F. Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr. Cancer Drug Targets 4(5), 443-454 (2004).
54. Pardridge WM, Buciak J, Yang J, Wu D. Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein. J. Pharmacol. Exp. Ther. 286(1), 548-554 (1998).
55. Carcenac M, Larroque C, Langlois R, Van Lier JE, Artus JC, Pélegrin A. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates. Photochem. Photobiol. 70(6), 930-936 (1999).
56. Shibaguchi H, Tsuru H, Kuroki M. Sonodynamic cancer therapy: a non-invasive and repeatable approach using low-intensity ultrasound with a sonosensitizer. Anticancer Res. 31(7), 2425-2429 (2011).
57. Abe H, Kuroki M, Tachibana K et al. Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anticancer Res. 22(3), 1575-1580 (2002).
58. Donald PJ, Cardiff RD, He DE, Kendall K. Monoclonal antibody-porphyrin conjugate for head and neck cancer: the possible magic bullet. Otolaryngol. Head Neck Surg. 105(6), 781-787 (1991).
59. Jiang FN, Liu DJ, Neyndorff H, Chester M, Jiang SY, Levy JG. Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J. Natl Cancer Inst. 83(17), 1218-1225 (1991).
60. Jiang FN, Richter AM, Jain AK, Levy JG, Smits C. Biodistribution of a benzoporphyrin derivative-monoclonal antibody conjugate in A549-tumor-bearing nude mice. Biotechnol. Ther. 4(1-2), 43-61 (1993).
61. Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular-endothelial- growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst. Rev. 7, CD008941 (2012).
62. Novichenko NL, Mamchur AA, Lisniak IO, Gamaliya MF. Study of photodynamic efficiency of the hematoporphyrin conjugated with antibody to VEGF in mouse Lewis carcinoma. Exp. Oncol. 30(4), 315-318 (2008).
63. Goff BA, Hermanto U, Rumbaugh J, Blake J, Bamberg M, Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br. J. Cancer 70(3), 474-480 (1994).
64. Goff BA, Blake J, Bamberg MP, Hasan T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br. J. Cancer 74(8), 1194-1198 (1996).
65. Lu XM, Fischman AJ, Stevens E et al. Sn-chlorin e6 antibacterial immunoconjugates. An in vitro and in vivo analysis. J. Immunol. Methods 156(1), 85-99 (1992).
66. Berthiaume F, Reiken SR, Toner M, Tompkins RG, Yarmush ML. Antibody-targeted photolysis of bacteria in vivo. Biotechnology (NY) 12(7), 703-706 (1994).
67. Schmidt S, Wagner U, Oehr P, Krebs D. Clinical use of photodynamic therapy in gynecologic tumor patients-antibody-targeted photodynamic laser therapy as a new oncologic treatment procedure. Zentralbl. Gynakol. 114(6), 307-311 (1992).
68. Schmidt S. Antibody-targeted photodynamic therapy. Hybridoma 12(5), 539-541 (1993).
69. Schmidt S, Wagner U, Schultes B et al. Photodynamic laser therapy with antibody-bound dyes. A new procedure in therapy of gynecologic malignancies. Fortschr. Med. 110(16), 298-301 (1992).